Adipokines: linking obesity and cardiovascular disease

References

• Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation67(5), 968–977 (1983).
   PubMed Web of Science ®Google Scholar
• Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann. Med.38, 52–63 (2006).
   PubMed Web of Science ®Google Scholar
• Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes Nat. Med.12(1), 62–66 (2006); erratum 12(3), 367 (2006).
   PubMed Web of Science ®Google Scholar
• Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care28(11), 2745–2749 (2005).
   PubMed Web of Science ®Google Scholar
• Berg A, Scherer P. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res.96(9), 939–949 (2005).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler. Thromb. Vasc. Biol.27(5), 996–1003 (2007).
   PubMed Web of Science ®Google Scholar
• Brunner H, Cockcroft JR, Deanfield J et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J. Hypertens.23(2), 233–246 (2005).
   PubMed Web of Science ®Google Scholar
• Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. FASEB J.3(9), 2007–2018 (1989).
   PubMed Web of Science ®Google Scholar
• Moncada S. Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin. Br. J. Pharmacol.76(1), 3–31 (1982).
   PubMed Web of Science ®Google Scholar
• Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium and modulates smooth muscle Ca2+ channels. J. Hypertens.6(4 Suppl.), S188–S191 (1988).
   Web of Science ®Google Scholar
• Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract. Res. Clin. Haematol.12(3), 329–341 (1999).
   PubMed Web of Science ®Google Scholar
• Collins T, Read MA, Neish AS et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-κ B and cytokine-inducible enhancers. FASEB J.9(10), 899–909 (1995).
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol.Metab.89(6), 2548–2556 (2004).
   PubMed Web of Science ®Google Scholar
• Kougias P, Chai H, Lin P et al. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J. Surg. Res.126(1), 121–129 (2005).
   PubMed Web of Science ®Google Scholar
• Wassink AMJ, Olijhoek JK, Visseren FLJ. The metabolic syndrome: metabolic changes with vascular consequences. Eur. J. Clin. Invest.37(1), 8–17 (2007).
   Google Scholar
• Satoh H, Nguyen MT, Trujillo M et al. Adenovirus-mediated adiponectin expression augments skeletal muscle insulin sensitivity in male Wistar rats. Diabetes54(5), 1304–1313 (2005).
   PubMed Web of Science ®Google Scholar
• Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med.7, 7 (2002).
   Google Scholar
• Gil-Campos M, Canete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr.23(5), 963–974 (2004).
   PubMed Web of Science ®Google Scholar
• Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun.257(1), 79–83 (1999).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation100(25), 2473–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Adamczak M, Wiecek A, Funahashi T et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am. J. Hypertens.16(1), 72–75 (2003).
   PubMed Web of Science ®Google Scholar
• Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler. Thromb. Vasc. Biol.23(1), 85–89 (2003).
   PubMed Web of Science ®Google Scholar
• Chen M-P, Tsai JCR, Chung F-M et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler. Thromb. Vasc. Biol.25(4), 821–826 (2005).
   PubMed Web of Science ®Google Scholar
• Kato H, Kashiwagi H, Shiraga M et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol.26(1), 224–230 (2006).
   PubMed Web of Science ®Google Scholar
• Dullaart RPF, de Vries R, van Tol A, Sluiter WJ. Lower plasma adiponectin is a marker of increased intima-media thickness associated with Type 2 diabetes mellitus and with male gender. Eur. J. Endocrinol.156(3), 387–394 (2007).
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA291(14), 1730–1737 (2004).
   PubMed Web of Science ®Google Scholar
• Chow W-S, Cheung BMY, Tso AWK et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension49(6), 1455–1461 (2007).
   PubMed Web of Science ®Google Scholar
• Sattar N, Wannamethee G, Sarwar N et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation114(7), 623–629 (2006).
   PubMed Web of Science ®Google Scholar
• Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin – a key adipokine in the metabolic syndrome. Diabetes Obes. Metab.8(3), 264–280 (2006).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ. Res.94(4), e27–e31 (2004).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation107(5), 671–674 (2003).
   PubMed Web of Science ®Google Scholar
• Hector J, Schwarzloh B, Goehring J et al. TNF-α alters visfatin and adiponectin levels in human fat. Horm. Metab. Res.39(4), 250–255 (2007).
   PubMed Web of Science ®Google Scholar
• Kubota N, Terauchi Y, Yamauchi T et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem.277(29), 25863–25866 (2002).
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo–vascular axis. J. Biol. Chem.277(40), 37487–37491 (2002).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension42(3), 231–234 (2003).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Kihara S, Ouchi N et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation106(22), 2767–2770 (2002).
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Arita Y, Nishida M et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab. Res.32(2), 47–50 (2000).
   PubMed Web of Science ®Google Scholar
• Ouedraogo R, Gong Y, Berzins B et al. Adiponectin deficiency increases leukocyte–endothelium interactions via upregulation of endothelial cell adhesion molecules in vivo. J. Clin. Invest.117(6), 1718–1726 (2007).
   PubMed Web of Science ®Google Scholar
• Hattori Y, Suzuki M, Hattori S, Kasai K. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia46(11), 1543–1549 (2003).
   PubMed Web of Science ®Google Scholar
• Thogersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation98(21), 2241–2247 (1998).
   PubMed Web of Science ®Google Scholar
• Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler. Thromb. Vasc. Biol.27(6), 1231–1237 (2007).
   PubMed Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med.342(24), 1792–1801 (2000).
   PubMed Web of Science ®Google Scholar
• Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J. Intern. Med.255(4), 448–456 (2004).
   PubMed Web of Science ®Google Scholar
• De Taeye BM, Novitskaya T, Gleaves L, Covington JW, Vaughan DE. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J. Biol. Chem.281(43), 32796–32805 (2006).
   Google Scholar
• Alessi M-C, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr. Opin. Lipidol.18(3), 240–245 (2007).
   PubMed Web of Science ®Google Scholar
• Samad F, Uysal KT, Wiesbrock SM et al. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl Acad. Sci. USA96(12), 6902–6907 (1999).
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest.95(5), 2409–2415 (1995).
   PubMed Web of Science ®Google Scholar
• Grau GE, Lou J. TNF in vascular pathology: the importance of platelet–endothelium interactions. Res. Immunol.144(5), 355–363 (1993).
   PubMedGoogle Scholar
• Rask-Madsen C, Dominguez H, Ihlemann N et al. Tumor necrosis factor-α inhibits insulin’s stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation108(15), 1815–1821 (2003).
   PubMed Web of Science ®Google Scholar
• Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-α contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J. Clin. Invest.100(11), 2777–2782 (1997).
   PubMed Web of Science ®Google Scholar
• Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc.60(3), 349–356 (2001).
   PubMed Web of Science ®Google Scholar
• Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler. Thromb. Vasc. Biol.19(10), 2348–2354 (1999).
   PubMed Web of Science ®Google Scholar
• Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet349(9050), 462–466 (1997).
   PubMed Web of Science ®Google Scholar
• Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care27(10), 2450–2457 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Daghri N, Chetty R, McTernan PG et al. Serum resistin is associated with C-reactive protein & LDL cholesterol in Type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc. Diabetol.4(1), 10 (2005).
   PubMed Web of Science ®Google Scholar
• Calabro P, Chang DW, Willerson JT, Yeh ETH. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J. Am. Coll. Cardiol.46(6), 1112–1113 (2005).
   PubMed Web of Science ®Google Scholar
• Pou K, Massaro J, Hoffmann U et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation116(11), 1234–1241 (2007).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation107(3), 363–369 (2003).
   PubMed Web of Science ®Google Scholar
• Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation113(17), 2135–2150 (2006).
   PubMed Web of Science ®Google Scholar
• Cirillo P, Golino P, Calabro P et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc. Res.68(1), 47–55 (2005).
   PubMedGoogle Scholar
• Singh P, Hoffmann M, Wolk R, Shamsuzzaman ASM, Somers VK. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol.27(9), e302–e307 (2007).
   Google Scholar
• Pelleymounter MA, Cullen MJ, Baker MB et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science269(5223), 540–543 (1995).
   PubMed Web of Science ®Google Scholar
• Stephens TW, Basinski M, Bristow PK et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature377(6549), 530–532 (1995).
   PubMed Web of Science ®Google Scholar
• Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA287(13), 1706–1709 (2002).
   PubMed Web of Science ®Google Scholar
• Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F et al. Relation of increased leptin concentrations to history of myocardial infarction and stroke in the United States population. Am. J. Cardiol.100(2), 234–239 (2007).
   PubMed Web of Science ®Google Scholar
• Lawlor DA, Smith GD, Kelly A, Sattar N, Ebrahim S. Leptin and coronary heart disease risk: prospective case control study of British women. Obesity (Silver Spring)15(7), 1694–1701 (2007).
   Google Scholar
• Schafer K, Halle M, Goeschen C et al. Leptin promotes vascular remodeling and neointimal growth in mice. Arterioscler. Thromb. Vasc. Biol.24(1), 112–117 (2004).
   PubMed Web of Science ®Google Scholar
• Bodary PF, Gu S, Shen Y et al. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol.25(8), e119–e122 (2005).
   Google Scholar
• Konstantinides S, Schafer K, Neels JG, Dellas C, Loskutoff DJ. Inhibition of endogenous leptin protects mice from arterial and venous thrombosis. Arterioscler. Thromb. Vasc. Biol.24(11), 2196–2201 (2004).
   PubMedGoogle Scholar
• Cottam DR, Mattar SG, Barinas-Mitchell E et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg.14(5), 589–600 (2004).
   PubMed Web of Science ®Google Scholar
• Crowley SD, Coffman TM. In hypertension the kidney rules. Curr. Hypertens. Rep.9(2), 148–153 (2007).
   Google Scholar
• Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc. Natl Acad. Sci. USA103(47), 17985–17990 (2006).
   PubMed Web of Science ®Google Scholar
• Vecchione C, Patrucco E, Marino G et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kγ. J. Exp. Med.201(8), 1217–1228 (2005).
   Google Scholar
• Massiera F, Bloch-Faure M, Ceiler D et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J.15(14), 2727–2729 (2001).
   PubMed Web of Science ®Google Scholar
• Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell104(4), 545–556 (2001).
   PubMed Web of Science ®Google Scholar
• Tham DM, Martin-McNulty B, Wang YX et al. Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs. Physiol. Genomics11(1), 21–30 (2002).
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin–angiotensin–aldosterone system. Hypertension45(3), 356–362 (2005).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature409(6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Verma S, Li S-H, Wang C-H et al. Resistin promotes endothelial cell activation: further evidence of adipokine–endothelial interaction. Circulation108(6), 736–740 (2003); erratum 109(18), 2254 (2004).
   PubMed Web of Science ®Google Scholar
• Kawanami D, Maemura K, Takeda N et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine–endothelial cell interactions. Biochem. Biophys. Res. Commun.314(2), 415–419 (2004).
   PubMed Web of Science ®Google Scholar
• Skilton MR, Nakhla S, Sieveking DP, Caterson ID, Celermajer DS. Pathophysiological levels of the obesity related peptides resistin and ghrelin increase adhesion molecule expression on human vascular endothelial cells. Clin. Exp. Pharmacol. Physiol.32(10), 839–844 (2005).
   PubMed Web of Science ®Google Scholar
• Diez JJ, Iglesias P, Fernandez-Reyes MJ et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with endstage renal disease. Clin. Endocrinol. (Oxford)62(2), 242–249 (2005).
   PubMed Web of Science ®Google Scholar
• Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J. Clin. Endocrinol. Metab.91(1), 64–68 (2006).
   PubMed Web of Science ®Google Scholar
• Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam. Horm.74, 443–477 (2006).
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest.112(12), 1796–1808 (2003).
   PubMed Web of Science ®Google Scholar
• Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia49(4), 744–747 (2006).
   PubMed Web of Science ®Google Scholar
• Permana PA, Menge C, Reaven PD. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem. Biophys. Res. Commun.341(2), 507–514 (2006).
   PubMed Web of Science ®Google Scholar
• Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α Arterioscler. Thromb. Vasc. Biol.25(10), 2062–2068 (2005).
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet366(9491), 1059–1062 (2005).
   PubMed Web of Science ®Google Scholar
• Lear SA, Humphries KH, Kohli S et al. Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke38(9), 2422–2429 (2007).
   PubMed Web of Science ®Google Scholar
• Kortelainen ML, Sarkioja T. Extent and composition of coronary lesions in relation to fat distribution in women younger than 50 years of age. Arterioscler. Thromb. Vasc. Biol.19(3), 695–699 (1999).
   PubMedGoogle Scholar
• Kortelainen ML, Sarkioja T. Visceral fat and coronary pathology in male adolescents. Int. J. Obes. Relat. Metab. Disord.25(2), 228–232 (2001).
   PubMedGoogle Scholar
• Alessi MC, Peiretti F, Morange P et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes46(5), 860–867 (1997).
   PubMed Web of Science ®Google Scholar
• Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab.83(3), 847–850 (1998).
   PubMed Web of Science ®Google Scholar
• Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes56(4), 1010–1013 (2007).
   PubMed Web of Science ®Google Scholar
• Harman-Boehm I, Bluher M, Redel H et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab.92(6), 2240–2247 (2007).
   PubMed Web of Science ®Google Scholar
• Bruun JM, Lihn AS, Pedersen SB, Richelsen B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab.90(4), 2282–2289 (2005).
   PubMed Web of Science ®Google Scholar
• Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol.7(12), 885–896 (2006).
   PubMed Web of Science ®Google Scholar
• Farmer SR. Transcriptional control of adipocyte formation. Cell Metab.4(4), 263–273 (2006).
   PubMed Web of Science ®Google Scholar
• Lacasa D, Taleb S, Keophiphath M, Miranville A, Clement K. Macrophagesecreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology148(2), 868–877 (2007).
   PubMed Web of Science ®Google Scholar
• Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and Type 2 diabetes mellitus. Ann. NY Acad. Sci.967, 363–378 (2002).
   PubMed Web of Science ®Google Scholar
• Bakker AHF, Van Dielen FMH, Greve JWM, Adam JA, Buurman WA. Preadipocyte number in omental and subcutaneous adipose tissue of obese individuals. Obes. Res.12(3), 488–498 (2004).
   PubMedGoogle Scholar
• Bahceci M, Gokalp D, Bahceci S et al. The correlation between adiposity and adiponectin, tumor necrosis factor α, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults? J. Endocrinol. Invest.30(3), 210–214 (2007).
   PubMed Web of Science ®Google Scholar
• Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab.92(3), 1023–1033 (2007).
   PubMed Web of Science ®Google Scholar
• Jernas M, Palming J, Sjoholm K et al. Separation of human adipocytes by size: hypertrophic fat cells display distinct gene expression. FASEB J.20(9), 1540–1542 (2006).
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Lenburg M, Thomou T et al. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab.292(1), E298–E307 (2007).
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Tchoukalova YD, Giorgadze N et al. Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am. J. Physiol. Endocrinol. Metab.288(1), E267–E277 (2005).
   PubMed Web of Science ®Google Scholar
• Goldstein DJ. Beneficial health effects of modest weight loss. Int. J. Obes. Relat. Metab. Disord.16(6), 397–415 (1992).
   PubMed Web of Science ®Google Scholar
• Bodary P, Eitzman D. Adiponectin: vascular protection from the fat? Arterioscler. Thromb. Vasc. Biol.26, 235–236 (2006).
   Google Scholar
• Cancello R, Henegar C, Viguerie N et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes54(8), 2277–2286 (2005).
   PubMed Web of Science ®Google Scholar
• Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA289(14), 1799–1804 (2003).
   PubMed Web of Science ®Google Scholar
• Repas TB. Challenges and strategies in managing cardiometabolic risk. J. Am. Osteopath. Assoc.107(4 Suppl 2), S4–S11 (2007).
   Google Scholar
• Batsis JA, Romero-Corral A, Collazo-Clavell ML et al. Effect of weight loss on predicted cardiovascular risk: change in cardiac risk after bariatric surgery. Obesity (Silver Spring)15(3), 772–784 (2007).
   Google Scholar
• Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. 26(5), 968–976 (2006).
   Google Scholar
• Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J. Clin. Endocrinol. Metab.86(8), 3815–3819 (2001); erratum 87(4), 1626 (2002).
   PubMed Web of Science ®Google Scholar
• Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med.36(3), 239–262 (2006).
   PubMed Web of Science ®Google Scholar
• Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce lowgrade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am. J. Physiol. Endocrinol. Metab.290(5), E961–E967 (2006).
   PubMed Web of Science ®Google Scholar
• Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesityrelated hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J. Clin. Endocrinol. Metab.90(11), 6192–6197 (2005).
   PubMed Web of Science ®Google Scholar
• Ryan AS, Nicklas BJ, Berman DM, Elahi D. Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int. J. Obes. Relat. Metab. Disord.27(9), 1066–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Boudou P, Sobngwi E, Mauvais-Jarvis F, Vexiau P, Gautier JF. Absence of exerciseinduced variations in adiponectin levels despite decreased abdominal adiposity and improved insulin sensitivity in Type 2 diabetic men. Eur. J. Endocrinol.149(5), 421–424 (2003).
   PubMed Web of Science ®Google Scholar
• Faraj M, Havel PJ, Phelis S et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab.88(4), 1594–1602 (2003).
   PubMed Web of Science ®Google Scholar
• O’Leary VB, Jorett AE, Marchetti CM et al. Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am. J. Physiol. Endocrinol. Metab.293(1), E421–E427 (2007).
   PubMedGoogle Scholar
• Polak J, Kovacova Z, Jacek M et al. An increase in plasma adiponectin multimeric complexes follows hypocaloric diet-induced weight loss in obese and overweight premenopausal women. Clin. Sci.112(11), 557–565 (2007).
   Google Scholar
• Coughlin CC, Finck BN, Eagon JC et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring)15(3), 640–645 (2007).
   Google Scholar
• Manco M, Fernandez-Real JM, Equitani F et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J. Clin. Endocrinol. Metab.92(2), 483–490 (2007).
   PubMed Web of Science ®Google Scholar
• Diker D, Vishne T, Maayan R et al. Impact of gastric banding on plasma adiponectin levels. Obes. Surg.16(8), 1057–1061 (2006).
   Google Scholar
• Swarbrick MM, Austrheim-Smith IT, Stanhope KL et al. Circulating concentrations of high-molecularweight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia49(11), 2552–2558 (2006).
   PubMedGoogle Scholar
• Sorensen TIA, Rissanen A, Korkeila M, Kaprio J. Intention to lose weight, weight changes, and 18-y mortality in overweight individuals without co-morbidities. PLoS Med.2(6), e171 (2005).
   PubMedGoogle Scholar
• Rzehak P, Meisinger C, Woelke G et al. Weight change, weight cycling and mortality in the ERFORT Male Cohort Study. Eur. J. Epidemiol.22(10), 665–673 (2007).
   PubMed Web of Science ®Google Scholar
• Diaz VA, Mainous AG 3rd, Everett CJ. The association between weight fluctuation and mortality: results from a population-based cohort study. J. Community Health30(3), 153–165 (2005).
   PubMed Web of Science ®Google Scholar
• Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. Diabetes Care27(3), 657–662 (2004).
   PubMed Web of Science ®Google Scholar
• Eilat-Adar S, Goldbourt U, Resnick HE, Howard BV. Intentional weight loss, blood lipids and coronary morbidity and mortality. Curr. Opin. Lipidol.16(1), 5–9 (2005).
   Google Scholar
• Eilat-Adar S, Eldar M, Goldbourt U. Association of intentional changes in body weight with coronary heart disease event rates in overweight subjects who have an additional coronary risk factor. Am. J. Epidemiol.161(4), 352–358 (2005).
   PubMed Web of Science ®Google Scholar
• Adams TD, Gress RE, Smith SC et al. Long-term mortality after gastric bypass surgery. N. Engl. J. Med.357(8), 753–761 (2007).
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Narbro K, Sjostrom CD et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med.357(8), 741–752 (2007).
   PubMed Web of Science ®Google Scholar
• Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet365(9468), 1389–1397 (2005); erratum 366(9483), 370 (2005).
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med.353(20), 2121–2134 (2005).
   PubMed Web of Science ®Google Scholar
• Bensaid M, Gary-Bobo M, Esclangon A et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol.63(4), 908–914 (2003).
   PubMed Web of Science ®Google Scholar
• Yan ZC, Liu DY, Zhang LL et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-δ. Biochem. Biophys. Res. Commun.354(2), 427–433 (2007).
   PubMed Web of Science ®Google Scholar
• Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation96(9), 3042–3047 (1997).
   PubMed Web of Science ®Google Scholar
• Maffei M, Halaas J, Ravussin E et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat. Med.1(11), 1155–1161 (1995).
   PubMed Web of Science ®Google Scholar